CA2650999A1 - Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies - Google Patents

Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies Download PDF

Info

Publication number
CA2650999A1
CA2650999A1 CA002650999A CA2650999A CA2650999A1 CA 2650999 A1 CA2650999 A1 CA 2650999A1 CA 002650999 A CA002650999 A CA 002650999A CA 2650999 A CA2650999 A CA 2650999A CA 2650999 A1 CA2650999 A1 CA 2650999A1
Authority
CA
Canada
Prior art keywords
substituted
compound
cancer
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002650999A
Other languages
English (en)
Inventor
Yang Young
Pranee Young
Martin Miranda
Michaela Pfahl
Bruce Carter
Mubarack Muthalif
Magnus Pfahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2650999A1 publication Critical patent/CA2650999A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
CA002650999A 2005-05-31 2006-05-30 Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies Abandoned CA2650999A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68606205P 2005-05-31 2005-05-31
US60/686,062 2005-05-31
PCT/US2006/020986 WO2006130613A2 (fr) 2005-05-31 2006-05-30 Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies

Publications (1)

Publication Number Publication Date
CA2650999A1 true CA2650999A1 (fr) 2006-12-07

Family

ID=37482228

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002650999A Abandoned CA2650999A1 (fr) 2005-05-31 2006-05-30 Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies

Country Status (6)

Country Link
EP (1) EP1896462A2 (fr)
JP (1) JP2008542382A (fr)
CN (1) CN101233129A (fr)
AU (1) AU2006252629A1 (fr)
CA (1) CA2650999A1 (fr)
WO (1) WO2006130613A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170098A (es) 2010-05-20 2017-07-17 Array Biopharma Inc Compuestos macrociclicos como inhibidores de quinasa trk
JP2014501496A (ja) * 2010-10-20 2014-01-23 ユニヴェルシテ ボルドー セガラン 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法
MX2018000577A (es) 2015-07-16 2018-09-05 Array Biopharma Inc Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa.
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
EP3571203B1 (fr) 2017-01-18 2023-06-07 Array BioPharma Inc. Composés de pyrazolo[1,5-a]pyrazine substitués utilisés en tant qu'inhibiteurs de la kinase ret
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
WO2020055672A1 (fr) 2018-09-10 2020-03-19 Array Biopharma Inc. Composés hétérocycliques condensés comme inhibiteurs de kinases ret

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020246T2 (de) * 1999-08-23 2006-01-19 Kyorin Pharmaceutical Co., Ltd. Substituierte benzylthiazolidin-2,4-dion derivate

Also Published As

Publication number Publication date
EP1896462A2 (fr) 2008-03-12
JP2008542382A (ja) 2008-11-27
WO2006130613A3 (fr) 2007-02-08
AU2006252629A1 (en) 2006-12-07
WO2006130613A2 (fr) 2006-12-07
CN101233129A (zh) 2008-07-30

Similar Documents

Publication Publication Date Title
CA2650999A1 (fr) Derives de biarylheterocycle substitues utilises comme inhibiteurs de la proteine kinase pour le traitement du cancer et d'autres maladies
JP5261575B2 (ja) 化学化合物
WO2013016720A2 (fr) Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies
EP1605946B1 (fr) Thiazoles utiles en tant qu'inhibiteurs des proteines kinases
AU2005230847B2 (en) Anaplastic lymphoma kinase modulators and methods of use
US20040097566A1 (en) 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
AU2013283318B2 (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
TW202003505A (zh) 甲基修飾酵素之調節劑、其組成物及用途
AU2013230425B2 (en) Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists
SK4772002A3 (en) Tyrosine kinase inhibitors, pharmaceutical composition containing the same and their use
JP5463592B2 (ja) アデノシンａ１レセプターアンタゴニストとしての新規化合物
BR112012000370B1 (pt) Compostos úteis como medicamentos
JP3555620B2 (ja) Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法
RU2391342C2 (ru) Новые азаиндолтиазолиноны в качестве противораковых агентов
US7897602B2 (en) Indolinone compounds as kinase inhibitors
JP2008504324A (ja) チアゾリノン非置換型キノリン
JP2005530705A (ja) 糖尿病および他の疾患を治療するための複素環アミド誘導体
CN101039939B (zh) 作为cdk1抑制剂的喹唑啉基亚甲基噻唑啉酮类
JP2019523237A (ja) 乳酸脱水素酵素の阻害剤としての１ｈ−ピラゾール−１−イル−チアゾールおよびそれらの使用方法
JP2008534646A (ja) Ｃｄｋ阻害剤としての置換１，５−ナフチリジンアゾリジノン
WO2006106721A1 (fr) Dérivé de pyrimidine ayant un effet d'inhibition de la tyrosine kinase
US20050014767A1 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
RU2758259C2 (ru) Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений
RU2395509C2 (ru) Тиазолинон-2-замещенные хинолины
EP2395001A1 (fr) Nouveaux dérivés de pyrimidine

Legal Events

Date Code Title Description
FZDE Dead